Oncology Brothers: Practice-Changing Cancer Discussions
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews...
Challenging Cases in Metastatic Pancreatic Cancer: Drs. Midhun Malla & Shafia Rahman
Welcome to the Oncology Brothers Podcast! In this episode, we discussed the complexities of pancreatic cancer treatment. Joined by two GI medical oncologists Dr. Midhun Malla, from the University of Alabama and Dr. Shafia Rahman, from the Ohio State University, where they discussed 2 challenging cases that highlighted the nuances of managing metastatic pancreatic adenocarcinoma.
Episode Highlights:
Case 1: A 63-year-old gentleman with a pancreatic head mass and multiple liver lesions. The discussion focuses on the importance of liquid and solid tissue next-generation sequencing (NGS) testing, treatment options including NALIRIFOX, modified FOLFIRINOX, and gemcitabine plus nab-paclitaxel, a...ESMO 2026 Breast Cancer Highlights: NATALEE, postMONARCH, TROPION-Breast02, INSPIRE-LM
Join us as we discussed the practice changing/informing studies presented at ESMO 2026. In this episode, we welcomed Dr. Javier Cortés, from Spain to discuss 4 key studies that are shaping the future of breast cancer treatment.
Episode Highlights:
NATALEE: An update on adjuvant ribociclib for T2N0 with high-risk features and node-positive disease, including its impact on overall survival (OS) and distant disease-free survival (DDFS) postMONARCH: Insights into the use of abemaciclib after prior CDK4/6 inhibitors in metastatic hormone receptor–positive breast cancer, focusing on progression-free survival (PFS) and OS outcomes TROPION-Breast02: A look...Neuroendocrine Tumor (NET) Management with Dr. Pamela Kunz - Treatment Algorithm
Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the complex world of neuroendocrine tumors (NETs) with renowned specialist Dr. Pamela Kunz, from Yale School of Medicine.
Join us as we explore:
The heterogeneous nature of neuroendocrine tumors, including differences in grade, origin, and functionality Diagnostic workups and the role of imaging, including the use of ⁶⁸Ga-DOTATATE positron emission tomography (PET) scans Treatment algorithms for both localized and metastatic NETs, focusing on somatostatin analogs, ¹⁷⁷Lu-DOTATATE, and other therapeutic options The importance of shared decision-making in treatment approaches, especially for asymptomatic patients M...Rectal Cancer Treatment Algorithm - Multidisciplinary Approach with Drs. Madhu Eluri & Nina Sanford
In this segment of the treatment algorithms, we focused on rectal cancer treatment landscape with Dr. Nina Sanford, a radiation oncologist, and Dr. Madhu Eluri, MD, a medical oncologist.
In this episode, we discussed:
The recent approval of dostarlimab for MSI-high rectal cancer and its implications for treatment The importance of a multidisciplinary approach in managing stage II and III rectal cancer The debate between total neoadjuvant treatment (TNT) versus the PROSPECT trial approach The role of chemotherapy, radiation, and surgery in various risk categories of rectal cancer How to monitor patients post-treatment and t...Management of Uncommon EGFR Mutations in NSCLC: Dr. Susan Scott
In this episode of the Oncology Brothers podcast, we dived deep into the world of uncommon EGFR mutations in non-small cell lung cancer (NSCLC). Joined by Dr. Susan Scott, a thoracic medical oncologist from the Johns Hopkins School of Medicine, as we explored the intricacies of EGFR exon 20 insertions, the third most common mutation, and other rare mutations such as G719X, S768I, and L861Q.
Key topics discussed include:
The importance of broad-based next-generation sequencing (NGS) testing for identifying EGFR mutations Current treatment options for exon 20 insertions, including the combination of amivantamab a...Durvalumab + Enfortumab vedotin FDA Approval for Muscle Invasive Bladder Cancer (MIBC): VOLGA
In this episode of the Oncology Brothers podcast, we welcomed Dr. Petros Grivas from Fred Hutch Cancer Center to discuss the recent FDA approval of the durvalumab plus enfortumab vedotin (EV) regimen for cisplatin-ineligible muscle-invasive bladder cancer (MIBC), based on the findings from the VOLGA trial.
Join us as we explored:
The evolution of treatment standards for MIBC over the past 2 years Key insights from the VOLGA trial, including study design, findings, and clinical implications The significance of event-free survival (EFS) and overall survival (OS) rates in the context of this new regimen The b...Management of NSCLC with Common EGFR Mutations: Dr. Ben Levy
We dived into this evolving landscape of treatment options for common sensitizing EGFR mutations in non-small cell lung cancer (NSCLC). In this episode, we were joined by Dr. Benjamin Levy, a thoracic medical oncologist at Johns Hopkins, to discuss the latest advances in frontline therapies, including single-agent osimertinib, osimertinib plus chemotherapy, and the promising combination of amivantamab and lazertinib.
Key topics covered include:
The prevalence of EGFR mutations in metastatic non-small cell adenocarcinoma The shift from single-agent osimertinib to combination therapies and the implications for patient care Factors influencing treatment decisions, including patient preference, s...ESMO 2026 Lung Cancer Highlights: DeLLphi-305, SAFFRON, KRASCENDO-1, PERSEE
Welcome back to the Oncology Brothers podcast! In this episode, we discussed practice changing/informing studies from the ESMO 2026 conference, focusing on the latest advancements in lung cancer treatment.
Join us as we welcomed Dr. Hossein Borghaei, a thoracic medical oncologist from the Fox Chase Cancer Center, to discuss 4 key studies that could change clinical practice:
DeLLphi-305: how the combination of durvalumab and tarlatamab after chemotherapy has led to a remarkable increase in median overall survival (OS) for patients with extensive-stage small cell lung cancer (ES-SCLC) SAFFRON: Learn about the efficacy of osimertinib combined w...ESMO 2026 GI Cancer Highlights: HERIZON-GEA-01, CLARITY-GASTRIC01, AZUR1, CHECKMATE 8HW, HARMONi-GI1
Welcome to the Oncology Brothers podcast! In this episode, we dived into the highlights from the ESMO 2026 conference, focusing on key studies in gastrointestinal (GI) malignancies.
Join us as we discussed:
HERIZON-GEA-01: Zanidatamab, a biparatopic HER2 antibody for HER2-positive upper GI adenocarcinoma, showcasing updated overall survival (OS) data and its implications for treatment CLARITY-Gastric 01: The first antibody-drug conjugate (ADC) targeting CLDN18.2, demonstrating significant improvements in OS for patients in the second- and third-line settings AZUR-1: Dostarlimab’s recent approval for MSI-high rectal cancer, highlighting its potential to allow patients to avoid radiation and sur...ESMO 2026 Head & Neck Melanoma Highlights OrigAMI-4, INTerpath-001, STARBOARD
In this discussion we dived into the latest breakthroughs in head and neck cancer and melanoma from ESMO 2026. In this episode, we welcomed Dr. Ari Rosenberg from the University of Chicago, to discuss promising data on amivantamab for HPV-negative head and neck cancer, including its efficacy in frontline settings and important considerations for managing side effects. We also had the opportunity to talk to Dr. Sapna Patel from the University of Colorado, who shared insights on the INTerpath-001 study, exploring the role of personalized mRNA vaccines in the adjuvant setting for melanoma.
Additionally, we discussed t...
RCC Management in Localized & Metastatic Disease with Dr. Monty Pal - Rapid-Fire Rounds
Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Sumanta "Monty" Pal, MD, a GU medical oncologist from the City of Hope, for a rapid-fire round discussing key questions from the oncology community about renal cell carcinoma (RCC).
Join us as we dived into topics including:
The standard of care for early-stage RCC and the role of adjuvant therapies like pembrolizumab with and without belzutifan Treatment strategies for oligometastatic disease and the use of radiation Insights on the use of circulating tumor DNA (ctDNA) in adjuvant settings and t...ESMO 2026 GU Highlights VOLGA, DASL-HiCAP, PROTEUS, KEYNOTE-564, LITESPARK-011
Welcome to the Oncology Brothers podcast! In this episode, we were joined by Drs. Shilpa Gupta and Ashish Kamat, to discuss the latest updates from ESMO 2026 in Madrid. With nearly 40,000 attendees and thousands of abstracts presented, we focus on the most impactful findings in genitourinary (GU) oncology.
Episode Highlights:
Muscle-Invasive Bladder Cancer (MIBC): A deep dive into the VOLGA trial, exploring the efficacy of neoadjuvant therapy with durvalumab and enfortumab vedotin (EV) in MIBC. We discussed the implications of reduced toxicity and potential changes to standard care. Non-Muscle-Invasive Bladder Cancer (NMIBC): Insights from the P...Multiple Myeloma CAR-T Management - Partners in Practice
In this episode of the Oncology Brothers podcast, we dived deep into the complexities of second-line treatment options for multiple myeloma, with a special focus on CAR T-cell therapy. Joined by experts Dr. Rafael Fonseca, a multiple myeloma specialist from the Mayo Clinic; Dr. Beth Faiman, a nurse practitioner specializing in myeloma; and Ms. Carrie Bellerive, a clinical nurse coordinator at Memorial Sloan Kettering Cancer Center, the discussion covers:
The eligibility criteria for CAR T-cell therapy and the data supporting its effectiveness Insights from recent clinical trials, including CARTITUDE-1 and CARTITUDE-2, highlighting long-term outcomes and potential f...
CAR-T Cell Therapy in Multiple Myeloma & Lymphoma - Clinical Foundations
Welcome to the Oncology Brothers podcast! In this episode, we dived into the world of CAR T-cell therapy, featuring insights from hematology experts Drs. Luciano Costa and Shernan Holtan.
Join us as we explore:
The basics of CAR T-cell therapy and the patient journey from referral to infusion The approved indications for CAR T-cell therapy in multiple myeloma and lymphoma, including the differences between idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) The importance of holding and bridging therapies to optimize patient outcomes The evolving landscape of side effects associated with CAR T-cell therapy, including a...Rapid Fire Rounds - Thrombocytopenia Workup & Management with Dr. Ronak Mistry
Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Ronak Mistry, a hematologist from Penn Medicine, for a rapid-fire round addressing common questions about thrombocytopenia.
We dived into a variety of topics, including:
Differentiating between inherited thrombocytopenia and mild immune thrombocytopenia (ITP) The role of steroids and bone marrow biopsy in diagnosis Management of anticoagulation in patients with low platelet counts Key distinctions between ITP, atypical hemolytic uremic syndrome (aHUS), and thrombotic thrombocytopenic purpura (TTP) Recent updates to ITP guidelines and the incorporation of new treatment options Thrombocytopenia in p...Challenging Cases in Small Cell Lung Cancer (SCLC) - Drs. Estela Rodriguez & Misty Shields
In this episode of the Oncology Brothers podcast, we dived into two challenging cases of small cell lung cancer (SCLC) to explore the latest supportive care options, the role of prophylactic cranial irradiation (PCI), and the sequencing of available treatments.
We were joined by Dr. Estela Rodriguez from the University of Miami and Dr. Misty Shields from the Indiana University, as they discussed:
A young woman with limited-stage SCLC undergoing concurrent chemotherapy and radiation, and the management of treatment-related cytopenias The implications of the recent MAVERICK trial comparing MRI surveillance to PCI and its i...WCLC 2026 Highlights: MAVERICK, ADAURA, HARMONi, PAPILLON, DESTINY-Lung04 with Dr. Christine Lovly
Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Christine Lovly, a thoracic medical oncologist from City of Hope, to discuss key studies presented at the World Conference on Lung Cancer 2026.
We dived into five pivotal studies, including:
MAVERICK: study on the role of MRI surveillance in small cell lung cancer (SCLC), showing that prophylactic cranial irradiation (PCI) may no longer be necessary ADAURA Update: 8-year update continues to show benefit of adjuvant osimertinib for early-stage EGFR-mutant lung cancer, with an impressive overall survival (OS) benefit HARMONi: potential of i...Managing Toxicities of HER2+ Therapies in Upper GI Cancer - Trastuzumab, T-DXd, Zanidatamab
Welcome to the Oncology Brothers podcast! In this episode, we dived into the latest advancements in HER2-targeted therapies for upper gastrointestinal malignancies, with Drs. Shruti Patel and Samuel Cytryn.
Join us as we discussed:
The recent approval of zanidatamab and its implications for HER2-positive esophageal and gastric adenocarcinoma The role of trastuzumab in treatment and its associated side effects, including cardiotoxicity and infusion reactions Addressing different dose used for trastuzumab deruxtecan (T-DXd) in upper GI space, along with important side effect profile to keep in mind The importance of shared decision-making in t...Upper GI Treatment Algorithm (Esophageal, Gastric, GEJ) - Dr. Sam Klempner
Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Samuel Klempner, a GI medical oncologist from the Massachusetts General Hospital, to discuss the evolving treatment landscape for upper gastrointestinal cancers, specifically esophageal, gastroesophageal junction (GEJ), and gastric adenocarcinoma.
During our discussion we touched on:
The treatment algorithm for localized disease, including the shift from local therapy to a combination of systemic and local treatments The current standard of care, which includes perioperative durvalumab with the FLOT regimen and surgery The role of chemoradiation therapy for patients who are not s...Follicular & Mantle Cell Lymphoma Treatment Algorithm: Dr. Jonathan Friedberg
In this episode of the Oncology Brothers podcast, we welcomed Dr. Jonathan Friedberg, a leading lymphoma expert, to discuss modern treatment approaches for follicular lymphoma and mantle cell lymphoma.
Join us as we explored:
The diagnostic workup for follicular lymphoma, including the role of bone marrow biopsy and staging imaging Treatment strategies for early-stage and symptomatic follicular lymphoma, including rituximab, obinutuzumab, and chemotherapy-based approaches The evolving role of maintenance therapy and what recent studies have shown about progression-free and overall survival New treatment options in relapsed/refractory follicular lymphoma, including tafasitamab and epcoritamab The i...Diffuse Large B-cell Lymphoma (DLBCL) Treatment Algorithm: Dr. Mazyar Shadman
In this episode of the Oncology Brothers podcast we had a chance to discuss the current treatment landscape for diffuse large B-cell lymphoma (DLBCL) with Dr. Mazyar Shadman, from the Fred Hutch Cancer Center.
We dived deep into frontline treatment options, including R-CHOP and polatuzumab-based regimens, and explored how to effectively risk stratify patients using the International Prognostic Index (IPI) score and the Hans algorithm. Dr. Shadman shared insights on the use of CAR T-cell therapy in both early and late relapsed settings, discussing the differences between axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), and t...
Revolution Medicines CEO Dr. Mark Goldsmith: Daraxonrasib dream to reality
Welcome to the Oncology Brothers podcast! In this episode, we dove deep into the groundbreaking advancements in pancreatic cancer treatment, focusing on the recent approval of daraxonrasib.
Join us as we welcome Mark Goldsmith, MD, PhD, CEO of Revolution Medicines, who shared his inspiring journey from clinical practice to the biotech industry. Discover the challenges and triumphs behind bringing this first-in-class drug to market, and learn about the significant impact it has on patient outcomes.
Keypoints:
Daraxonrasib is a first-in-class RAS inhibitor approved for the treatment of pancreatic cancer, targeting a...Camizestrant + CDK 46i FDA Approval in Hormone Receptor Positive Breast Cancer SERENA-6
Welcome to another episode of the Oncology Brothers! In this episode, we dived into the recent FDA approval of camizestrant for the treatment of hormone receptor–positive metastatic breast cancer, based on the SERENA-6 trial.
We welcomed Dr. Erica Mayer, a breast medical oncologist from the Dana-Farber Cancer Institute, who shared her insights on the trial's design, findings, and the significance of detecting ESR1 mutations before clinical progression. We discussed the implications of this approval, including the shift in treatment strategies, the importance of ctDNA monitoring, and the potential benefits for patient quality of life.
Ke...
SURPASS-ET: FDA Approval of Ropeginterferon alfa-2b in Essential Thrombocythemia (ET)
Welcome to the Oncology Brothers podcast! In this episode, we talked about the most recent developments in the world of myeloproliferative neoplasms (MPNs), including the exciting FDA approvals of ropeginterferon alfa-2b for essential thrombocythemia (ET) and rusfertide for polycythemia vera (PV).
The leading author Dr. John Mascarenhas, an MPN specialist from the Mount Sinai, New York, shared insights from the SURPASS-ET study, which paved the way for the official approval of ropeginterferon alfa-2b in ET. Dr. Mascarenhas discussed the study design, findings, and the implications of using ropeginterferon alfa-2b compared to traditional t...
Myelofibrosis Treatment Algorithm Discussion: Dr. Nico Gagelmann
Welcome to the Oncology Brothers podcast! In this episode, we had the opportunity to dive deep into the treatment algorithm for myelofibrosis with Dr. Nico Gagelmann of Dana-Farber Cancer Institute.
Join us as we explored:
The critical distinction between primary and secondary myelofibrosis and its implications for treatment The essential workup needed before initiating therapy, including bone marrow biopsy and mutation analysis Anemia management strategies, including the use of erythropoiesis-stimulating agents and the innovative drug luspatercept The role of JAK inhibitors in treatment, including ruxolitinib, momelotinib, pacritinib, and fedratinib, and how to choose among them b...Managing Toxicities of Therapies in Polycythemia Vera (PV) / Essential Thrombocythemia (ET)
Welcome back to the Oncology Brothers podcast! In this episode, we were joined by the MPN specialists Drs. Brandi Reeves and Naveen Pemmaraju, to discuss the treatment options for polycythemia vera (PV) and essential thrombocythemia (ET).
We dived deep into the side effect profiles and management strategies for key treatments, including:
Hydroxyurea: Learnt about dosing strategies, monitoring, and the importance of managing acute and chronic side effects such as leg ulcers and skin cancer risks Ropeginterferon alfa-2b: Discover the benefits and potential side effects, including flu-like symptoms and neuropsychiatric issues, and how to app...VERIFY: FDA Approval of Rusfertide in Polycythemia Vera (PV) - Dr. Andrew Kuykendall
Welcome to the Oncology Brothers podcast! In this episode, we dived into the recent approval of rusfertide for polycythemia vera, based on the findings from the VERIFY study. We were joined by Dr. Andrew Kuykendall, an MPN specialist from the Moffitt Cancer Center, who shared insights on the drug's mechanism of action as a hepcidin mimetic and its clinical implications.
Key topics discussed included:
The unique challenges of managing polycythemia vera, with balancing of erythrocytosis and iron deficiency The design and findings of the VERIFY study, highlighting the significant reduction in the need for phleb...Polycythemia vera (PV) and Essential thrombocythemia (ET) Treatment Algorithm: Dr. Aaron Gerds
Welcome to the Oncology Brothers podcast! In this episode, we are joined by Dr. Aaron Gerds, a hematologist from the Cleveland Clinic, to discuss the current treatment algorithms for myeloproliferative neoplasms (MPNs), specifically focusing on polycythemia vera (PV) and essential thrombocythemia (ET).
Join us as we delved into:
The diagnostic criteria for PV and ET, including the significance of JAK2 mutations and erythropoietin (EPO) levels The role of bone marrow biopsies in diagnosing and managing these conditions Treatment options for PV, including hydroxyurea, ropeginterferon alfa-2b, and ruxolitinib, as well as the approval of rusferti...Multiple Myeloma Management - Partners in Practice with Dr. Ajai Chari Team from UCSF
Welcome to the Oncology Brothers podcast! In this episode of our Partners in Practice series, we dived into the world of multiple myeloma treatment. We had the opportunity to engage with the dedicated team from UCSF, including Dr. Ajai Chari, a myeloma specialist, nurse practitioner Samantha Shenoy, NP, and clinical nurse Jenny Truong, RN.
In this insightful discussion, we covered:
The current standard of care for newly diagnosed multiple myeloma patients, focusing on quadruple therapy The role of anti-CD38 therapies like daratumumab and isatuximab in treatment regimens Patient expectations regarding side effects and the importance...HERIZON-GEA-01: FDA Approval of Zanidatamab + Tislelizumab for HER2+ Esophageai/GEJ/Gastric Adeno
We had a chance to dive into one of the most significant advancements in the treatment of HER2-positive gastroesophageal junction (GEJ) and gastric adenocarcinoma. In this episode, we discussed the groundbreaking HERIZON-GEA-01 study that led to the approval of zanidatamab, a novel bispecific HER2-directed antibody.
We welcomed Dr. Nataliya Uboha, a GI medical oncologist from the University of Wisconsin, who shared her insights on the study's design, findings, and the implications for clinical practice. Learn about the importance of biomarker testing, the mechanism of action of zanidatamab, and how it compares to traditional thera...
Rapid Fire Rounds - Multiple Myeloma Management with Dr. Joseph Mikhael
Welcome to the Oncology Brothers podcast and our new series, Rapid Fire Rounds! In this episode, we were joined by Dr. Joseph Mikhael, a myeloma specialist from the City of Hope, to answer 10–12 community-sourced questions on multiple myeloma management.
The panel covers:
Frontline therapy: Quadruplet therapy, carfilzomib vs bortezomib, and high-risk disease definitions Maintenance strategies: Lenalidomide alone vs daratumumab-lenalidomide vs carfilzomib-lenalidomide, with insights from the ENDURANCE, ATLAS trials Relapsed/refractory disease: Sequencing CAR T-cell therapy, bispecific antibodies (teclistamab + daratumumab), and the newly approved cereblon modulators (CELMoDs) like mezigdomide CAR-T logistics: The critical distinction between holding therap...EXCALIBER-RRMM - Iberdomide/Dara/Dex FDA Approval for R/R Multiple Myeloma: Dr. Sagar Lonial
Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Sagar Lonial, a myeloma specialist from the Emory University, to discuss the recent FDA approval of iberdomide, a novel cereblon modulator (CELMoDs), in combination with daratumumab and dexamethasone for the treatment of relapsed and refractory multiple myeloma.
Join us as we dive into:
The significance of the EXCALIBER-RRMM study that led to the approval of iberdomide What makes cereblon modulators different from existing immunomodulatory agents (IMiDs) and their potential benefits The study design, findings, and the implications of minimal residual disea...Managing Toxicities of Androgen Receptor Pathway Inhibitor (ARPI) in Prostate Cancer
Welcome to the Oncology Brothers podcast! In this episode, we discussed the world of androgen receptor pathway inhibitors (ARPIs) in prostate cancer as part of our Tox Check series. Joined by esteemed guests Dr. Alicia Morgans, a GU medical oncologist from Dana-Farber Cancer Institute, and Dr. Christopher M. Pieczonka, a urologist from US Urology Partners, the discussion covered the common side effects associated with ARPIs, including cardiac issues, cognitive changes, and more.
Key topics included:
An overview of approved ARPIs, focusing on abiraterone, apalutamide, darolutamide, and enzalutamide The importance of monitoring side effects and strateg...Challenging Cases in Myelodysplastic Syndrome (MDS) - Dr. Amer Zeidan
Join us with as we dive into two challenging cases of myelodysplastic syndromes (MDS) in this episode featuring Dr. Amer Zeidan, from the Yale School of Medicine. The discussion focused on real-life scenarios from community settings, exploring treatment decisions in both frontline settings and cases of disease progression.
In the first case, we examined a 74-year-old gentleman with persistent anemia and discussed the implications of his diagnosis, treatment options like erythropoiesis-stimulating agents (ESAs) and luspatercept, and the importance of timely intervention. The conversation highlighted the evolving landscape of MDS treatment, including the significance of molecular risk stratification an...
Treatment Algorithm of Myelodysplastic Syndrome (MDS) in 2026 - Dr. Thomas LeBlanc
Welcome to the Oncology Brothers podcast! In this episode, we were joined by Thomas LeBlanc, MD MA, from the Duke Cancer Institute to discuss the treatment algorithm for myelodysplastic syndrome (MDS).
We dived deep into the importance of risk stratification in MDS, exploring lower-risk, intermediate-risk, and higher-risk categories. Dr. LeBlanc shared insights on the role of next-generation sequencing (NGS) and the Revised International Prognostic Scoring System (IPSS-R) in guiding treatment decisions.
Key topics included:
Treatment options for lower-risk MDS, including the use of erythropoiesis-stimulating agents (ESAs) and luspatercept The significance of ring siderobl...Pancreatic Cancer Management - Partners in Practice with Dr. Tim Brown & Ms. Heather Kline
Join us in this insightful episode of our new series, Partners in Practice. We delved into the critical role of teamwork in cancer care, focusing on the treatment landscape of metastatic pancreatic cancer.
In this episode, we were joined by Dr. Timothy Brown, a GI medical oncologist from UT Southwestern, and Ms. Heather Kline, a GI-focused nurse practitioner. Together, we explored the latest treatment options, including modified FOLFIRINOX, NALIRIFOX, gemcitabine with nab-paclitaxel, and the emerging role of novel therapies like RAS inhibitors.
Key topics include:
Overview of current treatment paradigms for metastatic pancreatic cancer Discus...Treatment Algorithm of Late Relapsed/Refractory Multiple Myeloma (RRMM)
In this episode of the Oncology Brothers podcast, we dived deep into the complexities of late relapse refractory multiple myeloma treatment. Joined by Maximilian Merz, MD, a myeloma specialist from the Memorial Sloan Kettering Cancer Center, the discussion covered the evolving treatment landscape, including the use of CAR-T cell therapies, bispecific antibodies, and the importance of assessing BCMA expression.
Key topics included:
The current treatment algorithms for late relapse refractory multiple myeloma The significance of antigen expression in guiding treatment decisions The role of bispecific antibodies like teclistamab and talquetamab Managing side effects and improving patient...Treatment Algorithm of Early Relapsed/Refractory Multiple Myeloma (RRMM)
In this episode of the Oncology Brothers podcast we continued our treatment algorithm series, focusing on early relapsed/refractory multiple myeloma (RRMM). We were joined by Dr. Shaji Kumar, a myeloma specialist from the Mayo Clinic, who shared his insights into current evidence-based treatment strategies for patients whose disease has progressed after frontline therapy.
Key topics discussed included:
The current standard of care for frontline multiple myeloma, including quadruplet therapy and maintenance strategies The role of CAR T-cell therapy and bispecific antibodies, including teclistamab and talquetamab, in early relapsed/refractory multiple myeloma Treatment selection b...ENDURANCE Trial - Time-limited Lenalidomide Maintenance for Standard Risk Myeloma
Welcome to the Oncology Brothers podcast! In this episode, we dived into the latest advancements in multiple myeloma treatment, focusing on the practice changing ENDURANCE trial. Joined by esteemed guests Dr. Shaji Kumar and Dr. Vincent Rajkumar from Mayo Clinic, they discussed the new time limited approach being the standard of care for maintenance therapy in standard-risk multiple myeloma patients.
Key topics include:
Overview of the ENDURANCE trial and its implications for clinical practice The significance of limiting lenalidomide maintenance therapy to two years The role of minimal residual disease (MRD) testing in treatment deci...Managing Toxicities of CAR-T in Multiple Myeloma (MM) – Drs. Caitlin Costello & Joshua Richter
In this informative episode we dived into the world of CAR T-cell therapies for multiple myeloma. In this ToxCheck episode, we focused on the available CAR-T options, including idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), and discussed their side effects, management strategies, and the importance of patient education.
We were joined by myeloma specialists Caitlin Costello, MD, from UC San Diego Health, and Joshua Richter, MD, from Mount Sinai, who shared their insights on the acute and chronic side effects associated with CAR-T therapies. Learn about the common toxicities such as cytokine release syndrome (CRS) and immu...